Massive Bio

We’re heading to ESMO - European Society for Medical Oncology Congress 2025 in Berlin, Germany (October 17–21), continuing our mission to make clinical trial access faster, smarter, and more equitable for patients worldwide.   Our team, Selin Kurnaz, PhD (Co-founder & CEO), Mert Sari (Director, OUS Provider Engagement), Tuna Aydin (Director, OUS Provider Engagement) and Gisela Saladino (Key Account Manager, Spain) will be in the field connecting with oncology innovators, researchers, and partners.   We’re proud to be part of the global oncology dialogue alongside organizations shaping the future of cancer research and access, including AstraZeneca, Pfizer, Bristol Myers Squibb, and many more.   Let’s connect in Berlin to discuss how AI and clinical expertise together can redefine access to oncology innovation.   📅 Schedule a meeting with our team: https://bit.ly/4q5KGC6 #ESMO2025 #Oncology #ClinicalTrials #HealthInnovation Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our OUS Provider Engagement Director, Tuna Aydin, joined our partner Asklepieia Health Cluster at the Oncology and Medical Tourism: A New Era for Health in Greece event, hosted by the Athens Medical Association. During the session, Mr. George Kakoulidis from Asklepieia Health presented how Massive Bio’s AI-powered clinical trial matching technology is transforming how patients and oncologists discover trial opportunities. The night concluded with an engaging roundtable on breast and lung cancer clinical trials, highlighting the importance of accessibility and technology in expanding patient options across Greece. At Massive Bio, we continue working toward one goal, ensuring every patient, everywhere, can access the best possible clinical trial opportunities. #Oncology #ClinicalTrials #BreastCancer #LungCancer #HealthcareInnovation #Greece Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

We’re heading to #Berlin this November for the ESMO - European Society for Medical Oncology AI and Digital Health Congress 2025. You’ll find us at Booth #15, showcasing how Massive Bio is using #AI and real-world data to transform trial matching and prescreening hubs, making clinical trial enrollment faster, more efficient, and more equitable. 👉 If you’re attending, send us a quick message to schedule a meeting and connect with our team. 🔗 Contact us here: https://lnkd.in/gDbXFd7x Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our partner in Greece, Asklepieia Health Cluster, will talk about Massive Bio at the upcoming conference “Oncology and Medical Tourism: A New Era for Greece in Health” on September 25, 2025, in Athens. During the event, Mr. George Kakoulidis CEO of Asklepieia Health Cluster and Head of Development & Resources at Elitour Greek Health Tourism Council, will deliver a keynote titled: “Artificial Intelligence & Clinical Trials – How to Leverage AI in Clinical Trials by Massive Bio.” This conference will bring together leaders in oncology and healthcare to discuss the future of patient access and innovation in Greece. ━━━━━━━━━━━━━━━━━━━━ Ο συνεργάτης μας στην Ελλάδα, το Asklepieia Health Cluster, θα μιλήσει για τη Massive Bio στο επερχόμενο συνέδριο «Ογκολογία και Ιατρικός Τουρισμός: Μια Νέα Εποχή για την Υγεία στην Ελλάδα» στις 25 Σεπτεμβρίου 2025, στην Αθήνα. Κατά τη διάρκεια της εκδήλωσης, ο κ. Γιώργος Κακουλίδης, Διευθύνων Σύμβουλος του Asklepieia Health Cluster και Επικεφαλής Ανάπτυξης & Πόρων του Elitour Greek Health Tourism Council, θα δώσει την κεντρική ομιλία με τίτλο: «Τεχνητή Νοημοσύνη & Κλινικές Δοκιμές – Πώς να αξιοποιηθεί η ΤΝ στις Κλινικές Δοκιμές από τη Massive Bio.» Το συνέδριο θα φέρει κοντά ηγέτες στην ογκολογία και την υγειονομική περίθαλψη για να συζητήσουν το μέλλον της πρόσβασης των ασθενών και της καινοτομίας στην Ελλάδα. #AI #ClinicalTrials #Oncology Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

We were represented at the World Conference on Lung Cancer 2025, organized by the International Association for the Study of Lung Cancer (IASLC), by our Account Manager for Spain, Gisela Saladino. The conference brought together global experts to share the latest scientific and clinical advances in lung cancer. For us, it was an important opportunity to engage with the community, exchange insights, and stay aligned with innovations shaping the future of oncology. We remain committed to making clinical trials more accessible for patients and to supporting progress in lung cancer research worldwide. #IASLC #WCLC2025 #Oncology #ClinicalTrials Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Massive Bio continues to strengthen collaborations in Italy, meeting with leading physicians and institutions in #Florence, #Pisa, and #Empoli to advance clinical trial awareness and expand our Clinical Network. Alongside our Regional Manager Francesco Ulivieri and OUS Provider Engagement Director Mert Sari, we engaged with providers and associations including Azienda Ospedaliero Universitaria Pisana, San Rossore Medical Center, PO S. Chiara, AOU Pisana, and Azienda USL Toscana Centro Oncologia Medica PO San Giuseppe. These discussions are part of our ongoing commitment to connect patients with clinical trials and equip healthcare professionals with AI-driven solutions that improve access and accelerate research. #ClinicalTrials #AIinHealthcare #Oncology Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Ann Stevens, our Oncology Nurse Navigator, and a cancer survivo, carries a story that reminds us why Massive Bio exists. Her journey through cancer is not only one of resilience but also of purpose. Today, she channels that strength into guiding patients toward the right clinical trials, at the right time. At Massive Bio, we believe no one should face cancer alone. Ann’s story is proof that lived experience and innovation together can change lives. 👉 https://lnkd.in/d6SPCjUZ #CancerSurvivor #ClinicalTrials #Oncology #LifeSciences Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

We are proud to share that Massive Bio has been named a Best in Class Quarterfinalist in the AI in Patient Care category of The Digital Health Hub Foundation - Digital Health Awards 2025 🎉 Our focus has always been clear: use AI-powered precision matching to connect patients with the right clinical trials, accelerate enrollment, and support care teams. We’re glad to see this work acknowledged alongside other innovators shaping the future of healthcare. Finalists will be announced on October 4, winners revealed live at HLTH USA in Las Vegas on October 20, where you can also meet us at Booth 1760-34. Read more: https://lnkd.in/ddwW8jAY #AI #ClinicalTrials #DigitalHealth #HLTHUSA Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our co-founders Dr. Arturo LoAIza-Bonilla MD, Selin Kurnaz, PhD, and Çağatay M. Çulcuoğlu have co-authored the white paper: AI in Clinical Trials: An Executable, Equitable Operating System, framing the key themes we’ll be advancing at #DPHARM2025 in Philadelphia. The paper explores how AI can unify fragmented trial systems into a single, equitable operating framework, streamlining recruitment, improving interoperability, and expanding patient access. Meet Selin Kurnaz, PhD and our team at #DPHARM2025, Sept 16–17 at the Loews Philadelphia Hotel, Philadelphia, PA, where this vision will be part of the dialogue on the future of clinical research. 📖 Read the full paper: https://lnkd.in/dGAQapGv #AI #ClinicalTrials #DPHARM2025 #LifeSciences #Oncology #DigitalHealth

Absolutely thrilled for Massive Bio to be supporting this amazing event by Google Cloud!! Looking forward to see many of our colleagues leveraging AI to find cures and solutions for cancer patients!! 👏 #AI #cancer #clinicaltrials #neurosymbolic #CausalML St. Luke's University Health Network | American Society of Clinical Oncology (ASCO) | American Cancer Society | Blood Cancer United